Willenbring Lab »  Alumni »  Postdoctoral Fellows »  Aras N. Mattis, M.D., Ph.D.

Aras N. Mattis, M.D., Ph.D.

Assistant Professor, UCSF Department of Pathology

Contact Information

RMB 902D Box 0665
35 Medical Center Way
San Francisco, CA 94143
415.297.7901
aras.mattis@ucsfmedctr.org
Open Popup
  • University of California, Berkeley, B.A., Molecular and Cell Biology, 1998
  • University of Illinois, Chicago, M.D., Medicine, 2007
  • University of Illinois, Urbana-Champaign, Ph.D., Biochemistry, 2007
  • University of California, San Francisco, Anatomic Pathology Resident 2007-2009
  • University of California, San Francisco, Fellow, Surgical Pathology, 2009-2010
  • University of California, San Francisco, Fellow, Liver/GI Pathology, 2010-Present
  • American Board of Pathology, Anatomic Pathology
  • UCSF Department of Pathology
  • California Institute for Regenerative Medicine
  • Liver and Gastrointestinal Pathology
  • Development and metabolism, liver and gastrointestinal tumors, site-specific recombination.
  • Hepatocytes for transplant and disease modeling, micro-RNA regulation of hepatocyte
  • Liver diseases including metabolic, pediatric, fibrotic, idiopathic, stem cell derived

Aras N. Mattis, M.D., Ph.D., is a board-certified anatomic pathologist and clinical fellow in the Willenbring Lab. Dr. Mattis trained at the University of Illinois at Urbana-Champaign, earning both his doctorates, Biochemistry and Medicine, there in 2007. He continued his clinical training in Pathology at the University of California San Francisco completing residency in Anatomic Pathology with subsequent fellowship training in Surgical Pathology and Liver and gastrointestinal pathology under his clinical mentor, Dr. Linda Ferrell. Since 2010, he has worked in the Willenbring Lab, investigating the basic mechanisms of liver development and disease in the with a specific focus on liver metabolism and fatty liver disease as well as micro-RNA regulation of liver metabolism.

Dr. Mattis' postdoctoral work includes the use of translational human biopsy material as well as patient-derived induced pluripotent stem cell reprogramming to hepatocytes. As a long-term goal, this work aims to develop a humanized liver mouse model of fatty liver disease. Aras is supported by the UCSF CIRM clinical fellow training grant and continues to work closely with the UCSF Department of Pathology as a clinical researcher.

Most recent publications from a total of 13
  1. Choi WT, Tsai JH, Rabinovitch PS, Small T, Huang D, Mattis AN, Kakar S. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue. Gut. 2017 Jun 22. View in PubMed
  2. Marco-Rius I, Gordon JW, Mattis AN, Bok R, Delos Santos R, Sukumar S, Larson PEZ, Vigneron DB, Ohliger MA. Diffusion-weighted imaging of hyperpolarized [13 C]urea in mouse liver. J Magn Reson Imaging. 2017 Apr 17. View in PubMed
  3. Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. J Med Chem. 2016 Dec 22; 59(24):11161-11170. View in PubMed
  4. Frascoli M, Jeanty C, Fleck S, Moradi PW, Keating S, Mattis AN, Tang Q, MacKenzie TC. Heightened Immune Activation in Fetuses with Gastroschisis May Be Blocked by Targeting IL-5. J Immunol. 2016 Jun 15; 196(12):4957-66. View in PubMed
  5. Zdravkovic T, Nazor KL, Larocque N, Gormley M, Donne M, Hunkapillar N, Giritharan G, Bernstein HS, Wei G, Hebrok M, Zeng X, Genbacev O, Mattis A, McMaster MT, Krtolica A, Valbuena D, Simón C, Laurent LC, Loring JF, Fisher SJ. Human stem cells from single blastomeres reveal pathways of embryonic or trophoblast fate specification. Development. 2015 Dec 1; 142(23):4010-25. View in PubMed
  6. Mattis AN, Song G, Hitchner K, Kim RY, Lee AY, Sharma AD, Malato Y, McManus MT, Esau CC, Koller E, Koliwad S, Lim LP, Maher JJ, Raffai RL, Willenbring H. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology. 2015 Jan; 61(1):141-52. View in PubMed
  7. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 2014 Apr 3; 508(7494):93-7. View in PubMed
  8. Mattis AN, Willenbring H. A ZFN/piggyBac step closer to autologous liver cell therapy. Hepatology. 2012 Jun; 55(6):2033-5. View in PubMed
  9. Levy M, Trivedi A, Zhang J, Miles L, Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, Xu H, Dhall D, Wang HL. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol. 2012 May; 43(5):695-701. View in PubMed
  10. Baker-LePain JC, Stone DH, Mattis AN, Nakamura MC, Fye KH. Clinical diagnosis of segmental arterial mediolysis: differentiation from vasculitis and other mimics. Arthritis Care Res (Hoboken). 2010 Nov; 62(11):1655-60. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Aras N. Mattis, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X